PeptideForward
Home / Peptides / Tesamorelin
Growth Hormone

Tesamorelin: uses, research, and availability

Growth-hormone-releasing hormone analog (Egrifta)

An FDA-approved GHRH analog used to reduce excess visceral abdominal fat in a specific patient group.

Class: GHRH analog Common use: Visceral fat reduction Route: Prescription Reviewed: May 2026
✅ Available now: Tesamorelin is an FDA-approved prescription medication. A licensed provider can prescribe it today for patients who meet clinical criteria. It does not depend on the 2026 peptide review.

What is Tesamorelin?

Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH), marketed as Egrifta. It is FDA-approved to reduce excess abdominal fat in people with HIV-associated lipodystrophy.

Because it is an approved medication, it can be prescribed now by a licensed provider for patients who meet the approved criteria.

How it is thought to work

Tesamorelin stimulates the pituitary gland to release the body's own growth hormone through the GHRH pathway. The resulting effects can help reduce deep abdominal (visceral) fat in eligible patients.

What the research shows

Clinical trials in the approved population demonstrated reductions in visceral adipose tissue. Evidence outside the approved indication is more limited, and a provider can explain what applies to your situation.

Our editorial standard

We summarize published research and do not make therapeutic promises. A licensed provider can evaluate whether any therapy is appropriate for you. Treat any source promising guaranteed results with skepticism.

Approved uses

  • Reduction of excess visceral abdominal fat (per approved use)
  • HIV-associated lipodystrophy
  • Support of the growth-hormone axis

Tesamorelin is FDA-approved and available now by prescription for its approved use. It does not depend on the 2026 peptide review.

How to access Tesamorelin legitimately

A licensed provider determines whether you meet the approved criteria and, if so, prescribes the product through a licensed pharmacy with appropriate monitoring.

PeptideForward can match you with vetted telehealth providers who handle these therapies through legitimate channels. The eligibility check takes about five minutes and there is no cost to see if you are a candidate.

Frequently asked questions

Is tesamorelin a weight-loss drug? It is approved specifically to reduce excess visceral fat in HIV-associated lipodystrophy, not as a general weight-loss medication. A provider can discuss appropriate options for your goal.

Is it available now? Yes, for its approved use, prescribed by a licensed provider.

Does PeptideForward sell it? No. We are an education and matching service only.

Stay informed

Get 2026 peptide updates

One email when the FDA advisory committee decides, plus plain-language updates as access evolves. No spam.